H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 19.12 CNY -5.3% Market Closed
Market Cap: 11.5B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Bacterin Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Total Equity
ÂĄ6.3B
CAGR 3-Years
42%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Equity
ÂĄ25.1B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Equity
ÂĄ12.7B
CAGR 3-Years
71%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Equity
ÂĄ30.7B
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
24%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Equity
ÂĄ31.5B
CAGR 3-Years
32%
CAGR 5-Years
47%
CAGR 10-Years
29%
Imeik Technology Development Co Ltd
SZSE:300896
Total Equity
ÂĄ6.3B
CAGR 3-Years
12%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
11.5B CNY
Industry
Biotechnology

Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Intrinsic Value
30.08 CNY
Undervaluation 36%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Total Equity?
Total Equity
6.3B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Total Equity amounts to 6.3B CNY.

What is Hualan Biological Bacterin Inc's Total Equity growth rate?
Total Equity CAGR 5Y
48%

Over the last year, the Total Equity growth was 14%. The average annual Total Equity growth rates for Hualan Biological Bacterin Inc have been 42% over the past three years , 48% over the past five years .

Back to Top